APLT vs. CMPS, IGMS, ALT, AVBP, PAHC, ABUS, CALT, ANAB, GHRS, and SLRN
Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include COMPASS Pathways (CMPS), IGM Biosciences (IGMS), Altimmune (ALT), ArriVent BioPharma (AVBP), Phibro Animal Health (PAHC), Arbutus Biopharma (ABUS), Calliditas Therapeutics AB (publ) (CALT), AnaptysBio (ANAB), GH Research (GHRS), and Acelyrin (SLRN). These companies are all part of the "pharmaceutical preparations" industry.
COMPASS Pathways (NASDAQ:CMPS) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, community ranking, institutional ownership, valuation, profitability, media sentiment, analyst recommendations, earnings and dividends.
COMPASS Pathways has higher earnings, but lower revenue than Applied Therapeutics. COMPASS Pathways is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
COMPASS Pathways currently has a consensus target price of $47.40, suggesting a potential upside of 462.95%. Applied Therapeutics has a consensus target price of $11.60, suggesting a potential upside of 144.73%. Given Applied Therapeutics' higher probable upside, research analysts clearly believe COMPASS Pathways is more favorable than Applied Therapeutics.
46.2% of COMPASS Pathways shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 24.0% of COMPASS Pathways shares are owned by company insiders. Comparatively, 19.1% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
COMPASS Pathways has a beta of 2.48, indicating that its stock price is 148% more volatile than the S&P 500. Comparatively, Applied Therapeutics has a beta of 1.81, indicating that its stock price is 81% more volatile than the S&P 500.
Applied Therapeutics received 23 more outperform votes than COMPASS Pathways when rated by MarketBeat users. However, 76.19% of users gave COMPASS Pathways an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
COMPASS Pathways' return on equity of 0.00% beat Applied Therapeutics' return on equity.
In the previous week, Applied Therapeutics had 3 more articles in the media than COMPASS Pathways. MarketBeat recorded 7 mentions for Applied Therapeutics and 4 mentions for COMPASS Pathways. COMPASS Pathways' average media sentiment score of 0.63 beat Applied Therapeutics' score of 0.30 indicating that Applied Therapeutics is being referred to more favorably in the news media.
Summary
Applied Therapeutics beats COMPASS Pathways on 8 of the 14 factors compared between the two stocks.
Get Applied Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Applied Therapeutics Competitors List
Related Companies and Tools
